APOLLOHOSP.NS Apollo Hospitals Enterprise Limited
INR·Price 8393.50·Mkt cap 1.21TComputed from the latest reported financials and the current market price.
Who's the real player?
A genuine play on this theme — most of its business sits right here.
Is the business healthy?
Shaky fundamentals — weak cash generation or a stretched balance sheet. Tread carefully.
- ⚠Weak FCF conversion (<50% of net income turns into free cash)
- Strong growth quality
- Healthy balance sheet
- Positive operating cash flow to EBITDA ratio
Are the smart people buying?
No ownership-change data for this stock. Conviction is judged from capex and buyback signals alone.
- Institutional stake at 50.49%
- Insider net buys
- Capex growth of 14.56%
What is management saying?
No earnings-call transcript or filings found for this stock.
Is the price right?
Intrinsic value 982.19 vs price 8393.50 — screens expensive on a cash-flow DCF (-88.3% to intrinsic). The base FCF growth assumption of 15% appears high and may not be sustainable without additional context.
| Intrinsic / share | 982.19 |
| Price | 8393.50 |
| Upside to intrinsic | -88.3% |
| Reverse-DCF implied g | 40.2% |
Base FCF 7.00B · growth 15.0% · discount 12.0% · terminal 5.0%.
Sensitivity — intrinsic value / share
Each cell is the intrinsic value at that growth (across →) and discount rate (down ↓). Center ★ is the base case. Cells green = above price (cheap), red = below (expensive).
| Growth rate → | |||||
|---|---|---|---|---|---|
| Disc ↓ ╲ g | 11% | 13% | 15% | 17% | 19% |
| 10% | 1097.44 | 1370.68 | 1687.97 | 2055.72 | 2481.13 |
| 11% | 805.07 | 1022.68 | 1274.87 | 1566.63 | 1903.59 |
| 12% | 597.36 | 775.8 | ★ 982.19 | 1220.53 | 1495.34 |
| 13% | 442.48 | 592 | 764.61 | 963.58 | 1192.61 |
| 14% | 322.76 | 450.17 | 596.96 | 765.87 | 959.97 |
Through the masters' eyes
Each investor's numeric rules, checked against this stock's metrics: exact math, no guesswork. Tap one to see which rules pass, fail, and what to judge yourself.
▶
Passes 2 of 2 of Raamdeo Agrawal's numeric checks. Still judge the non-numeric criteria below for yourself.
- Quality: ROCE ≥ 18% — now 18.4%
- Longevity: revenue consistency ≥ 70% — now 99.5%
- Durability of the growth (longevity)
- Quality and honesty of management
Couldn't check from available data: Growth: earnings CAGR ≥ 15% — not available; Price: PEG ≤ 2 — not available
▶
Passes 2 of 2 of Vijay Kedia's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 15% — now 20.5%
- Manageable debt (D/E ≤ 1.0) — now 0.9
- Ambitious, capable management
- A small company with a large opportunity
- Patience to hold for years
Couldn't check from available data: Strong earnings growth ≥ 20% — not available
▶
Passes 3 of 4 of Charlie Munger's numeric checks. Still judge the non-numeric criteria below for yourself.
- High returns on capital (ROCE ≥ 15%) — now 18.4%
- ROE ≥ 15% — now 20.5%
- Conservative leverage (D/E ≤ 1.0) — now 0.9
- Trades below intrinsic value (margin of safety ≥ 0) — now -754.6%
- A high-quality, understandable business
- A durable moat
- Management of integrity
▶
Passes 3 of 4 of Radhakishan Damani's numeric checks. Still judge the non-numeric criteria below for yourself.
- High returns on capital (ROCE ≥ 18%) — now 18.4%
- Consistent revenue (consistency ≥ 80%) — now 99.5%
- Positive net margin — now 7.7%
- Very low debt (D/E ≤ 0.5) — now 0.9
- A durable consumer franchise
- Pricing power
- A long runway, bought patiently
▶
Passes 2 of 3 of Rakesh Jhunjhunwala's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 18% — now 20.5%
- Conservative leverage (D/E ≤ 1.0) — now 0.9
- Net margin ≥ 10% — now 7.7%
- A large, scalable opportunity
- Trustworthy, ambitious management
- Conviction to hold through volatility
Couldn't check from available data: Earnings growth ≥ 15% — not available
▶
Passes 3 of 5 of Warren Buffett's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 15% — now 20.5%
- Positive free cash flow — now 3.5%
- Conservative leverage (D/E ≤ 1.0) — now 0.9
- Net margin ≥ 10% — now 7.7%
- Trades below intrinsic value (margin of safety ≥ 0) — now -754.6%
- A business you can understand
- A durable competitive moat
- Honest, capable management
▶
Passes 1 of 2 of Peter Lynch's numeric checks. Still judge the non-numeric criteria below for yourself.
- Manageable debt (D/E ≤ 1.0) — now 0.9
- Solid liquidity (current ratio ≥ 1.5) — now 1.06
- A simple business you understand
- Which 'type' it is (fast grower, stalwart, cyclical…)
- A believable growth story
Couldn't check from available data: PEG ≤ 1 (growth cheap vs price) — not available; Earnings growth ≥ 15% — not available
▶
Passes 2 of 6 of Benjamin Graham's numeric checks. Still judge the non-numeric criteria below for yourself.
- Debt below equity (D/E ≤ 1.0) — now 0.9
- Financially safe (Altman Z ≥ 3) — now 7.05
- P/E ≤ 15 — now 62.53
- P/B ≤ 1.5 — now 12.81
- Graham number: P/E × P/B ≤ 22.5 — now 801
- Strong liquidity (current ratio ≥ 1.5) — now 1.06
- A long record of stable earnings
- An uninterrupted dividend history
Financial statements (INR)
↗ sourceCash-flow lines highlighted — we trust cash over reported profit.
| Line | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 252.28B | 217.94B | 188.62B | 164.45B | — |
| Operating income | 28.93B | 22.64B | 17.07B | 14.49B | — |
| EBITDA | 39.87B | 32.55B | 24.78B | 20.73B | — |
| Net income | 19.42B | 14.46B | 8.99B | 8.19B | — |
| Operating cash flow | 28.56B | 21.36B | 19.20B | 13.77B | — |
| Capex | -19.62B | -17.13B | -11.37B | -11.29B | — |
| Free cash flow | 8.94B | 4.24B | 7.83B | 2.48B | — |
| Total assets | 221.97B | 206.57B | 167.53B | 144.28B | — |
| Total equity | 94.80B | 82.12B | 69.35B | 61.97B | — |
| Total debt | 84.93B | 54.19B | 53.33B | 43.32B | — |
| Cash & equivalents | 8.11B | 5.78B | 5.05B | 4.33B | — |